Gene therapy for rheumatoid arthritis: Recent advances

Current Gene Therapy

Volumn 8, Issue 1, 2008, Pages 24-41

  Woods, James M ^a   Sitabkhan, Yasmin ^a   Koch, Alisa E ^b  

^a MIDWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Adeno associated virus; Angiogenesis; Animal models; Apoptosis; Contralateral effect; Electrotransfer; Interleukin 10; Signaling

Indexed keywords

ADENOVIRUS VECTOR; ANGIOSTATIN; CYTOKINE; ENDOSTATIN; ETANERCEPT; FAS LIGAND; IMMUNOGLOBULIN G1; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 18 BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 4; MATRIX METALLOPROTEINASE INHIBITOR; NAKED DNA; PARVOVIRUS VECTOR; PLASMID DNA; PROTEIN P75; RECOMBINANT INTERLEUKIN 10; RIBOZYME; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 1;

ANEMIA; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; CELL BASED GENE THERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG SYNTHESIS; ELECTROPORATION; ENZYME INHIBITION; EXTRACELLULAR MATRIX; GENE TARGETING; HUMAN; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PATIENT COMPLIANCE; REVIEW; RHEUMATOID ARTHRITIS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SYNOVECTOMY; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ARTHRITIS, RHEUMATOID; GENE THERAPY; HUMANS;

ADENO-ASSOCIATED VIRUS; ANIMALIA;

EID: 41849151730     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652308783688482     Document Type: Review

References (119)

1. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 350: 2167-2179 (2004).
2. Evans CH, Ghivizzani SC, Robbins PD. Will arthritis gene therapy become a clinical reality? Nat Clin Pract Rbeurnatol 2: 344-345 (2006).
3. Siatskas C, Chan J, Field J, et al. Gene therapy strategies towards immune tolerance to treat the autoimmune diseases. Curr Gene Ther 6: 45-58 (2006).
4. Woods JM, Koch AE. Cytokine gene therapy for the treatment of rheumatoid arthritis. In: Eds Mazda O, Immuno-gene Therapy. Kerala, India, Research Signpost; pp 141-172 (2004).
5. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419 (2003).
6. Chernajovsky Y, Gould DJ, Podhajcer OL. Gene therapy for autoimmune diseases: quo vadis? Nat Rev Immunol 4: 800-811 (2004).
7. Evans CH, Gouze E, Gouze JN, Robbins PD, Ghivizzani SC. Gene therapeutic approaches-transfer in vivo. Adv Drug Deliv Rev 58: 243-258 (2006).
8. Moritz F, Distler O, Ospelt C, Gay RE, Gay S. Technology insight: gene transfer and the design of novel treatments for rheumatoid arthritis. Nat Clin Pract Rheumatol 2: 153-162 (2006).
9. Tarner IH, Neumann E, Gay S, Fathman CG, Muller-Ladner U. Developing the concept of adoptive cellular gene therapy of rheumatoid arthritis. Autoimmun Rev 5: 148-152 (2006).
10. Bloquel C, Bessis N, Boissier MC, Scherman D, Bigey P. Gene therapy of collagen-induced arthritis by electrotransfer of human tumor necrosis factor-alpha soluble receptor I variants. Hum Gene Ther 15: 189-201 (2004).
11. Hur W, Cho ML, Yoon SK, et al. Adenoviral delivery of IL-1 receptor antagonist abrogates disease activity during the development of autoimmune arthritis in IL-1 receptor antagonist-deficient mice. Immunol Lett 106: 154-162 (2006).
12. Kim JM, Jeong JG, Ho SH, et al. Protection against collagen-induced arthritis by intramuscular gene therapy with an expression plasmid for the interleukin-1 receptor antagonist. Gene Ther 10: 1543-1550 (2003).
13. Smeets RL, Joosten LA, Arntz OJ, et al. Soluble interleukin-1 receptor accessory protein ameliorates collagen-induced arthritis by a different mode of action from that of interleukin-1 receptor antagonist. Arthritis Rheum 52: 2202-2211 (2005).
14. Smeets RL, van de Loo FA, Joosten LA, et al. Effectiveness of the soluble form of the interleukin-1 receptor accessory protein as an inhibitor of interleukin-1 in collagen-induced arthritis. Arthritis Rheum 48: 2949-2958 (2003).
15. Smith R, Tarner IH, Hollenhorst M, et al. Localized expression of an anti-TNF single-chain antibody prevents development of collagen-induced arthritis. Gene Ther 10: 1248-1257 (2003).
16. Smeets RL, van de Loo FA, Arntz OJ, et al. Adenoviral delivery of IL-18 binding protein C ameliorates collagen-induced arthritis in mice. Gene Ther 10: 1004-1011 (2003).
17. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev 12: 53-72 (2001).
18. Celiker MY, Ramamurthy N, Xu JW, et al. Inhibition of adjuvant-induced arthritis by systemic tissue inhibitor of metalloproteinases 4 gene delivery. Arthritis Rheum 46: 3361-3368 (2002).
19. Nabbe KC, van Lent PL, Holthuysen AE, et al. Local IL-13 gene transfer prior to immune-complex arthritis inhibits chondrocyte death and matrix-metalloproteinase-mediated cartilage matrix degradation despite enhanced joint inflammation. Arthritis Res Ther 7: R392-401 (2005).
20. Rutkauskaite E, Volkmer D, Shigeyama Y, et al. Retroviral gene transfer of an antisense construct against membrane type 1 matrix metalloprotemase reduces the invasiveness of rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 52: 2010-2014 (2005).
21. Rutkauskaite E, Zacharias W, Schedel J, et al. Ribozymes that inhibit the production of matrix metalloproteinase 1 reduce the invasiveness of rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 50: 1448-1456 (2004).
22. Schedel J, Seemayer CA, Pap T, et al. Targeting cathepsin L (CL) by specific ribozymes decreases CL protein synthesis and cartilage destruction in rheumatoid arthritis. Gene Ther 11: 1040-1047 (2004).
23. van der Laan WH, Quax PH, Seemayer CA, et al. Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of TIMP-1 and TIMP-3. Gene Ther 10: 234-242 (2003).
24. Woods JM, Amin MA, Katschke KJ, Jr., et al. Interleukin-13 gene therapy reduces inflammation, vascularization, and bony destruction in rat adjuvant-induced arthritis. Hum Gene Ther 13: 381-393 (2002).
25. Woods JM, Katschke KJ, Jr., Tokuhira M, et al. Reduction of inflammatory cytokines and prostaglandin E2 by IL-13 gene therapy in rheumatoid arthritis synovium. J Immunol 165: 2755-2763 (2000).
26. Haas CS, Amin MA, Ruth JH, et al. In vivo inhibition of angiogenesis by interleukin-13 gene therapy in a rat model of rheumatoid arthritis. Arthritis Rheum 56: 2535-2548 (2007).
27. Afuwape AO, Feldmann M, Paleolog EM. Adenoviral delivery of soluble VEGF receptor 1 (sFIt-1) abrogates disease activity in murine collagen-induced arthritis. Gene Ther 10: 1950-1960 (2003).
28. Chen Y, Donnelly E, Kobayashi H, Debusk LM, Lin PC. Gene therapy targeting the Tie2 function ameliorates collagen-induced arthritis and protects against bone destruction. Arthritis Rheum 52: 1585-1594 (2005).
29. Haas CS, Amin MA, Allen BB, et al. Inhibition of angiogenesis by interleukin-4 gene therapy in rat adjuvant-induced arthritis. Arthritis Rheum 54: 2402-2414 (2006).
30. Jou IM, Shiau AL, Chen SY, et al. Thrombospondin 1 as an effective gene therapeutic strategy in collagen-induced arthritis. Arthritis Rheum 52: 339-344 (2005).
31. Kato K, Miyake K, Igarashi T, Yoshino S, Shimada T. Human immunodeficiency virus vector-mediated intra-articular expression of angiostatin inhibits progression of collagen-induced arthritis in mice. Rheumatol Int 25: 522-529 (2005).
32. Takahashi H, Kato K, Miyake K, et al. Adeno-associated virus vector-mediated anti-angiogenic gene therapy for collagen-induced arthritis in mice. Clin Exp Rbeumatol 23: 455-461 (2005).
33. Wang CR, Chen SY, Wu CL, et al. Prophylactic adenovirus-mediated human kallistatin gene therapy suppresses rat arthritis by inhibiting angiogenesis and inflammation. Arthritis Rheum 52: 1319-1324 (2005).
34. Volpert OV, Fong T, Koch AE, et al. Inhibition of angiogenesis by interleukin 4. J Exp Med 188: 1039-1046 (1998).
35. Woods JM, Katschke KJ, Volin MV, et al. IL-4 adenoviral gene therapy reduces inflammation, proinflammatory cytokines, vascularization, and bony destruction in rat adjuvant-induced arthritis. J Immunol 166: 1214-1222 (2001).
36. Aoudjehane L, Podevin P, Scatton O, et al. Interleukin-4 induces human hepatocyte apoptosis through a Fas-independent pathway. FASEB J 21: 1433-1444 (2007).
37. Guillot C, Coathalem H, Chetritt J, et al. Lethal hepatitis after gene transfer of IL-4 in the liver is independent of immune responses and dependent on apoptosis of hepatocytes: a rodent model of IL-4-induced hepatitis. J Immunol 166: 5225-5235 (2001).
38. Hotary K, Allen E, Punturieri A, Yana I, Weiss SJ. Regulation of cell invasion and morphogenesis in a three-dimensional type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3. J Cell Biol 149: 1309-1323 (2000).
39. Ohno-Matsui K, Uetama T, Yoshida T, et al. Reduced retinal angiogenesis in MMP-2-deficient mice. Invest Ophthalmol Vis Sci 44: 5370-5375 (2003).
40. Kobayashi H, Takeno M, Saito T, et al. Regulatory role of heme oxygenase 1 in inflammation of rheumatoid arthritis. Arthritis Rheum 54: 1132-1142 (2006).
41. Ke B, Shen XD, Zhai Y, et al. Heme oxygenase 1 mediates the immunomodulatory and antiapoptotic effects of interleukin 13 gene therapy in vivo and in vitro. Hum Gene Ther 13: 1845-1857 (2002).
42. Mountz JD, Hsu HC, Matsuki Y, Zhang HG. Apoptosis and rheumatoid arthritis: past, present, and future directions. Curr Rheumatol Rep 3: 70-78 (2001).
43. Hasunuma T, Kayagaki N, Asahara H, et al. Accumulation of soluble Fas in inflamed joints of patients with rheumatoid arthritis. Arthritis Rheum 40: 80-86 (1997).
44. Perlman H, Pagliari LJ, Georganas C, et al. FLICE-inhibitory protein expression during macrophage differentiation confers resistance to fas-mediated apoptosis. J Exp Med 190: 1679-1688 (1999).
45. Zhang H, Gao G, Clayburne G, Schumacher HR. Elimination of rheumatoid synovium in situ using a Fas ligand 'gene scalpel'. Arthritis Res Ther 7: R1235-1243 (2005).
46. Kim SH, Kim S, Oligino TJ, Robbins PD. Effective treatment of established mouse collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express FasL. Mol Ther 6: 584-590 (2002).
47. Liu Z, Xu X, Hsu HC, et al. CII-DC-AdTRAIL cell gene therapy inhibits infiltration of CII-reactive T cells and CII-induced arthritis. J Clin Invest 112: 1332-1341 (2003).
48. Yao Q, Wang S, Gambotto A, et al. Intra-articular adenoviral-mediated gene transfer of trail induces apoptosis of arthritic rabbit synovium. Gene Ther 10: 1055-1060 (2003).
49. Evans CH, Ghivizzani SC, Robbins PD. Gene therapy for arthritis: what next? Arthritis Rheum 54: 1714-1729 (2006).
50. Makarov SS. NF-kappa B in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, and tissue destruction. Arthritis Res 3: 200-206 (2001).
51. Miagkov AV, Kovalenko DV, Brown CE, et al. NF-kappaB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc Natl Acad Sci U S A 95: 13859-13864 (1998).
52. Makarov SS, Johnston WN, Olsen JC, et al. NF-kappa B as a target for anti-inflammatory gene therapy: suppression of inflammatory responses in monocytic and stromal cells by stable gene transfer of I kappa B alpha cDNA. Gene Ther 4: 846-852 (1997).
53. Tas SW, Adriaansen J, Hajji N, et al. Amelioration of arthritis by intraarticular dominant negative Ikk beta gene therapy using adeno-associated virus type 5. Hum Gene Ther 17: 821-832 (2006).
54. Schett G, Tohidast-Akrad M, Smolen JS, et al. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 43: 2501-2512 (2000).
55. Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ. Increasing complexity of Ras signaling. Oncogene 17: 1395-1413 (1998).
56. Roivainen A, Soderstrom KO, Pirila L, et al. Oncoprotein expression in human synovial tissue: an immunohistochemical study of different types of arthritis. Br J Rbeumatol 35: 933-942 (1996).
57. Yamamoto A, Fukuda A, Seto H, et al. Suppression of arthritic bone destruction by adenovirus-mediated dominant-negative Ras gene transfer to synoviocytes and osteoclasts. Arthritis Rheum 48: 2682-2692 (2003).
58. Bessis N, Cottard V, Saidenberg-Kermanach N, et al. Syngeneic fibroblasts transfected with a plasmid encoding interleukin-4 as non-viral vectors for anti-inflammatory gene therapy in collagen-induced arthritis. J Gene Med 4: 300-307 (2002).
59. Kageyama Y, Koide Y, Uchijima M, et al. Plasmid encoding interleukin-4 in the amelioration of murine collagen-induced arthritis. Arthritis Rheum 50: 968-975 (2004).
60. Saidenberg-Kermanac'h N, Bessis N, Lemeiter D, et al. Interleukin-4 cellular gene therapy and osteoprotegerin decrease inflammation-associated bone resorption in collagen-induced arthritis. J Clin Immunol 24: 370-378 (2004).
61. Tamer IH, Nakajima A, Seroogy CM, et al. Retroviral gene therapy of collagen-induced arthritis by local delivery of IL-4. Clin Immunol 105: 304-314 (2002).
62. Neidhart M, Jungel A, Ospelt C, et al. Deficient expression of interleukin-10 receptor alpha chain in rheumatoid arthritis synovium: limitation of animal models of inflammation. Arthritis Rheum 52: 3315-3318 (2005).
63. Saidenberg-Kermanac'h N, Bessis N, Deleuze V, et al. Efficacy of interleukin-10 gene electrotransfer into skeletal muscle in mice with collagen-induced arthritis. J Gene Med 5: 164-171 (2003).
64. Kuroda T, Maruyama H, Shimotori M, et al. Effects of viral interleukin 10 introduced by in vivo electroporation on arthrogen-induced arthritis in mice. J Rheumatol 33: 455-462 (2006).
65. Neumann E, Judex M, Kullmann F, et al. Inhibition of cartilage destruction by double gene transfer of IL-lRa and IL-10 involves the activin pathway. Gene Ther 9: 1508-1519 (2002).
66. Khoury M, Bigey P, Louis-Plence P, et al. A comparative study on intra-articular versus systemic gene electrotransfer in experimental arthritis. J Gene Med 8: 1027-1036 (2006).
67. Apparailly F, Millet V, Noel D, et al. Tetracycline-inducible interleukin-10 gene transfer mediated by an adeno-associated virus: application to experimental arthritis. Hum Gene Ther 13: 1179-1188 (2002).
68. Deleuze V, Scherman D, Bureau ME. Interleukin-10 expression after intramuscular DNA electrotransfer: kinetic studies. Biochem Biophys Res Commun 299: 29-34 (2002).
69. Apparailly F, Verwaerde C, Jacquet C, et al. Adenovirus-mediated transfer of viral IL-10 gene inhibits murine collagen-induced arthritis. J Immunol 160: 5213-5220 (1998).
70. Joosten LA, Lubberts E, Durez P, et al. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritis Rheum 40: 249-260 (1997).
71. Kim KN, Watanabe S, Ma Y, et al. Viral IL-10 and soluble TNF receptor act synergistically to inhibit collagen-induced arthritis following adenovirus-mediated gene transfer. J Inummol 164: 1576-1581 (2000).
72. Ma Y, Thornton S, Duwel LE, et al. Inhibition of collagen-induced arthritis in mice by viral IL- 10 gene transfer. J Immunol 161: 1516-1524 (1998).
73. Quattrocchi E, Dallman MJ, Dhillon AP, et al. Murine IL-10 gene transfer inhibits established collagen-induced arthritis and reduces adenovirus-mediated inflammatory responses in mouse liver. J Immunol 166: 5970-5978 (2001).
74. Whalen JD, Lechman EL, Carlos CA, et al. Adenoviral transfer of the viral IL-10 gene periarticularly to mouse paws suppresses development of collagen-induced arthritis in both injected and uninjected paws. J Immunol 162: 3625-3632 (1999).
75. Perez N, Plence P, Millet V, et al. Tetracycline transcriptional silencer tightly controls transgene expression after in vivo intramuscular electrotransfer: application to interleukin 10 therapy in experimental arthritis. Hum Gene Ther 13: 2161-2172 (2002).
76. Fedorak RN, Gangl A, Elson CO, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 119: 1473-1482 (2000).
77. Keystone E, Wherry J, Grint P. IL-10 as a therapeutic strategy in the treatment of rheumatoid arthritis. Rheum Dis Clin North Am 24: 629-639 (1998).
78. Tilg H, Ulmer H, Kaser A, Weiss G. Role of IL-10 for induction of anemia during inflammation. J Inummol 169: 2204-2209 (2002).
79. Woods AM, Thompson SJ, Wooley PH, Panayi G, Klavinskis LS. Immune modulation of collagen-induced arthritis by intranasal cytokine gene delivery: a model for the therapy of rheumatoid arthritis. Arthritis Rheum 52: 3761-3771 (2005).
80. Bessis N, Lemeiter D, Laroche L, et al. Engraftment of cutaneous fibroblasts within synovial membrane in a nonhuman primate: short-term results. Joint Bone Spine 74: 48-51 (2007).
81. Kumar R, Dammai V, Yadava PK, Kleinau S. Gene targeting by ribozyme against TNF-alpha mRNA inhibits autoimmune arthritis. Gene Ther 12: 1486-1493 (2005).
82. Adriaansen J, Vervoordeldonk MJ, Vanderbyl S, de Jong G, Tak PP. A novel approach for gene therapy: engraftment of fibroblasts containing the artificial chromosome expression system at the site of inflammation. J Gene Med 8: 63-71 (2006).
83. Tiera MJ, Winnik FO, Fernandes JC. Synthetic and natural polycations for gene therapy: state of the art and new perspectives. Curr Gene Ther 6: 59-71 (2006).
84. Dai L, Claxson A, Marklund SL, et al. Amelioration of antigen-induced arthritis in rats by transfer of extracellular superoxide dismutase and catalase genes. Gene Ther 10: 550-558 (2003).
85. Favard C, Dean DS, Rols MP. Electrotransfer as a non viral method of gene delivery. Curr Gene Ther 7: 67-77 (2007).
86. Nishikawa M, Huang L. Nonviral vectors in the new millennium: delivery barriers in gene transfer. Hum Gene Ther 12: 861-870 (2001).
87. Grossin L, Cournil-Henrionnet C, Mir LM, et al. Direct gene transfer into rat articular cartilage by in vivo electroporation. FASEB J 17: 829-835 (2003).
88. Kreiss P, Bettan M, Crouzet J, Scherman D. Erythropoietin secretion and physiological effect in mouse after intramuscular plasmid DNA electrotransfer. J Gene Med 1: 245-250 (1999).
89. Maruyama H, Sugawa M, Moriguchi Y, et al. Continuous erythropoietin delivery by muscle-targeted gene transfer using in vivo electroporation. Hum Gene Ther 11: 429-437 (2000).
90. Rizzuto G, Cappelletti M, Maione D, et al. Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation. Proc Nall Acad Sci U S A 96: 6417-6422 (1999).
91. Gould DJ, Bright C, Chernajovsky Y. Inhibition of established collagen-induced arthritis with a tumour necrosis factor-alpha inhibitor expressed from a self-contained doxycycline regulated plasmid. Arthritis Res Ther 6: R103-113 (2004).
92. Jeong JG, Kim JM, Ho SH, et al. Electrotransfer of human IL-1Ra into skeletal muscles reduces the incidence of murine collagen-induced arthritis. J Gene Med 6: 1125-1133 (2004).
93. Kim JM, Ho SH, Hahn W, et al. Electro-gene therapy of collagen-induced arthritis by using an expression plasmid for the soluble p75 tumor necrosis factor receptor-Fc fusion protein. Gene Ther 10: 1216-1224 (2003).
94. Samulski RJ. AAV vectors, the future workhorse of human gene therapy. Ernst Schering Res Found Workshop 25-40 (2003).
95. Snyder RO, Francis J. Adeno-associated viral vectors for clinical gene transfer studies. Curr Gene Ther 5: 311-321 (2005).
96. Lai CM, Lai YK, Rakoczy PE. Adenovirus and adeno-associated virus vectors. DNA Cell Biol 21: 895-913 (2002).
97. Ponnazhagan S, Erikson D, Kearns WG, et al. Lack of site-specific integration of the recombinant adeno-associated virus 2 genomes in human cells. Hum Gene Ther 8: 275-284 (1997).
98. Wang Z, Ma HI, Li J, et al. Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther 10: 2105-2111 (2003).
99. Arai Y, Kubo T, Fushiki S, et al. Gene delivery to human chondrocytes by an adeno associated virus vector. J Rheumatol 27: 979-982 (2000).
100. Madry H, Cucchiarini M, Terwilliger EF, Trippel SB. Recombinant adeno-associated virus vectors efficiently and persistently transduce chondrocytes in normal and osteoarthritic human articular cartilage. Hum Gene Ther 14: 393-402 (2003).
101. Ulrich-Vinther M, Duch MR, Soballe K, et al. In vivo gene delivery to articular chondrocytes mediated by an adeno-associated virus vector. J Orthop Res 22: 726-734 (2004).
102. Goater J, Muller R, Kollias G, et al. Empirical advantages of adeno associated viral vectors in vivo gene therapy for arthritis. J Rheumatol 27: 983-989 (2000).
103. Pan RY, Chen SL, Xiao X, et al. Therapy and prevention of arthritis by recombinant adeno-associated virus vector with delivery of interleukin-1 receptor antagonist. Arthritis Rheum 43: 289-297 (2000).
104. Pan RY, Xiao X, Chen SL, et al. Disease-inducible transgene expression from a recombinant adeno-associated virus vector in a rat arthritis model. J Virol 73: 3410-3417 (1999).
105. Watanabe S, Imagawa T, Boivin GP, et al. Adeno-associated virus mediates long-term gene transfer and delivery of chondroprotective IL-4 to murine synovium. Mol Ther 2: 147-152 (2000).
106. Jennings K, Miyamae T, Traister R, et al. Proteasome inhibition enhances AAV-mediated transgene expression in human synoviocytes in vitro and in vivo. Mol Ther 11: 600-607 (2005).
107. Chan JM, Villarreal G, Jin WW, et al. Intraarticular gene transfer of TNFR:Fc suppresses experimental arthritis with reduced systemic distribution of the gene product. Mol Ther 6: 727-736 (2002).
108. Conlon TJ, Flotte TR. Recombinant adeno-associated virus vectors for gene therapy. Expert Opin Biol Ther 4: 1093-1101 (2004).
109. Ghivizzani SC, Lechman ER, Kang R, et al. Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor alpha soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects. Proc Natl Acad Sci U S A 95: 4613-4618 (1998).
110. Lechman ER, Jaffurs D, Ghivizzani SC, et al. Direct adenoviral gene transfer of viral IL-10 to rabbit knees with experimental arthritis ameliorates disease in both injected and contralateral control knees. J Immunol 163: 2202-2208 (1999).
111. Boyle DL, Nguyen KH, Zhuang S, et al. Intra-articular IL-4 gene therapy in arthritis: anti-inflammatory effect and enhanced th2activity. Gene Ther 6: 1911-1918 (1999).
112. Kim SH, Lechman ER, Kim S, et al. Ex vivo gene delivery of IL-1Ra and soluble TNT receptor confers a distal synergistic therapeutic effect in antigen-induced arthritis. Mol Ther 6: 591-600 (2002).
113. Lechman ER, Keravala A, Nash J, et al. The contralateral effect conferred by intra-articular adenovirus-mediated gene transfer of viral IL-10 is specific to the immunizing antigen. Gene Ther 10: 2029-2035 (2003).
114. Kim SH, Lechman ER, Bianco N, et al. Exosomes derived from IL-10-treated dendritic cells can suppress inflammation and collagen-induced arthritis. J Immunol 174: 6440-6448 (2005).
115. Evans CH, Robbins PD, Ghivizzani SC, et al. Gene transfer to human joints: progress toward a gene therapy of arthritis. Proc Natl Acad Sci USA 102: 8698-8703 (2005).
116. Wadman M. Gene therapy might not have caused patient's death. Nature 449: 270 (2007).
117. Kaiser J. Clinical research. Death prompts a review of gene therapy vector. Science 317: 580 (2007).
118. Hughes V. Therapy on trial. Nat Med 13: 1008-1009 (2007).
119. Kaiser J. Gene therapy. Questions remain on cause of death in arthritis trial. Science 317: 1665 (2007).